List of Chapters/Sections(Table Of Content)
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2027)
1.4.2 East Asia Market States and Outlook (2022-2027)
1.4.3 Europe Market States and Outlook (2022-2027)
1.4.4 South Asia Market States and Outlook (2022-2027)
1.4.5 Southeast Asia Market States and Outlook (2022-2027)
1.4.6 Middle East Market States and Outlook (2022-2027)
1.4.7 Africa Market States and Outlook (2022-2027)
1.4.8 Oceania Market States and Outlook (2022-2027)
1.4.9 South America Market States and Outlook (2022-2027)
1.5 Global Neurologic Disorders Therapeutics Market Size Analysis from 2022 to 2027
1.5.1 Global Neurologic Disorders Therapeutics Market Size Analysis from 2022 to 2027 by Consumption Volume
1.5.2 Global Neurologic Disorders Therapeutics Market Size Analysis from 2022 to 2027 by Value
1.5.3 Global Neurologic Disorders Therapeutics Price Trends Analysis from 2022 to 2027
1.6 COVID-19 Outbreak: Neurologic Disorders Therapeutics Industry Impact
Chapter 2 Global Neurologic Disorders Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Neurologic Disorders Therapeutics (Volume and Value) by Type
2.1.1 Global Neurologic Disorders Therapeutics Consumption and Market Share by Type (2016-2021)
2.1.2 Global Neurologic Disorders Therapeutics Revenue and Market Share by Type (2016-2021)
2.2 Global Neurologic Disorders Therapeutics (Volume and Value) by Application
2.2.1 Global Neurologic Disorders Therapeutics Consumption and Market Share by Application (2016-2021)
2.2.2 Global Neurologic Disorders Therapeutics Revenue and Market Share by Application (2016-2021)
2.3 Global Neurologic Disorders Therapeutics (Volume and Value) by Regions
2.3.1 Global Neurologic Disorders Therapeutics Consumption and Market Share by Regions (2016-2021)
2.3.2 Global Neurologic Disorders Therapeutics Revenue and Market Share by Regions (2016-2021)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2016-2021 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2016-2021 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Neurologic Disorders Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
4.1 Global Neurologic Disorders Therapeutics Consumption by Regions (2016-2021)
4.2 North America Neurologic Disorders Therapeutics Sales, Consumption, Export, Import (2016-2021)
4.3 East Asia Neurologic Disorders Therapeutics Sales, Consumption, Export, Import (2016-2021)
4.4 Europe Neurologic Disorders Therapeutics Sales, Consumption, Export, Import (2016-2021)
4.5 South Asia Neurologic Disorders Therapeutics Sales, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Neurologic Disorders Therapeutics Sales, Consumption, Export, Import (2016-2021)
4.7 Middle East Neurologic Disorders Therapeutics Sales, Consumption, Export, Import (2016-2021)
4.8 Africa Neurologic Disorders Therapeutics Sales, Consumption, Export, Import (2016-2021)
4.9 Oceania Neurologic Disorders Therapeutics Sales, Consumption, Export, Import (2016-2021)
4.10 South America Neurologic Disorders Therapeutics Sales, Consumption, Export, Import (2016-2021)
Chapter 5 North America Neurologic Disorders Therapeutics Market Analysis
5.1 North America Neurologic Disorders Therapeutics Consumption and Value Analysis
5.1.1 North America Neurologic Disorders Therapeutics Market Under COVID-19
5.2 North America Neurologic Disorders Therapeutics Consumption Volume by Types
5.3 North America Neurologic Disorders Therapeutics Consumption Structure by Application
5.4 North America Neurologic Disorders Therapeutics Consumption by Top Countries
5.4.1 United States Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
5.4.2 Canada Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
5.4.3 Mexico Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
Chapter 6 East Asia Neurologic Disorders Therapeutics Market Analysis
6.1 East Asia Neurologic Disorders Therapeutics Consumption and Value Analysis
6.1.1 East Asia Neurologic Disorders Therapeutics Market Under COVID-19
6.2 East Asia Neurologic Disorders Therapeutics Consumption Volume by Types
6.3 East Asia Neurologic Disorders Therapeutics Consumption Structure by Application
6.4 East Asia Neurologic Disorders Therapeutics Consumption by Top Countries
6.4.1 China Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
6.4.2 Japan Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
6.4.3 South Korea Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
Chapter 7 Europe Neurologic Disorders Therapeutics Market Analysis
7.1 Europe Neurologic Disorders Therapeutics Consumption and Value Analysis
7.1.1 Europe Neurologic Disorders Therapeutics Market Under COVID-19
7.2 Europe Neurologic Disorders Therapeutics Consumption Volume by Types
7.3 Europe Neurologic Disorders Therapeutics Consumption Structure by Application
7.4 Europe Neurologic Disorders Therapeutics Consumption by Top Countries
7.4.1 Germany Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
7.4.2 UK Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
7.4.3 France Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
7.4.4 Italy Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
7.4.5 Russia Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
7.4.6 Spain Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
7.4.7 Netherlands Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
7.4.8 Switzerland Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
7.4.9 Poland Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
Chapter 8 South Asia Neurologic Disorders Therapeutics Market Analysis
8.1 South Asia Neurologic Disorders Therapeutics Consumption and Value Analysis
8.1.1 South Asia Neurologic Disorders Therapeutics Market Under COVID-19
8.2 South Asia Neurologic Disorders Therapeutics Consumption Volume by Types
8.3 South Asia Neurologic Disorders Therapeutics Consumption Structure by Application
8.4 South Asia Neurologic Disorders Therapeutics Consumption by Top Countries
8.4.1 India Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
8.4.2 Pakistan Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Neurologic Disorders Therapeutics Market Analysis
9.1 Southeast Asia Neurologic Disorders Therapeutics Consumption and Value Analysis
9.1.1 Southeast Asia Neurologic Disorders Therapeutics Market Under COVID-19
9.2 Southeast Asia Neurologic Disorders Therapeutics Consumption Volume by Types
9.3 Southeast Asia Neurologic Disorders Therapeutics Consumption Structure by Application
9.4 Southeast Asia Neurologic Disorders Therapeutics Consumption by Top Countries
9.4.1 Indonesia Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
9.4.2 Thailand Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
9.4.3 Singapore Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
9.4.4 Malaysia Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
9.4.5 Philippines Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
9.4.6 Vietnam Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
9.4.7 Myanmar Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
Chapter 10 Middle East Neurologic Disorders Therapeutics Market Analysis
10.1 Middle East Neurologic Disorders Therapeutics Consumption and Value Analysis
10.1.1 Middle East Neurologic Disorders Therapeutics Market Under COVID-19
10.2 Middle East Neurologic Disorders Therapeutics Consumption Volume by Types
10.3 Middle East Neurologic Disorders Therapeutics Consumption Structure by Application
10.4 Middle East Neurologic Disorders Therapeutics Consumption by Top Countries
10.4.1 Turkey Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
10.4.3 Iran Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
10.4.5 Israel Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
10.4.6 Iraq Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
10.4.7 Qatar Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
10.4.8 Kuwait Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
10.4.9 Oman Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
Chapter 11 Africa Neurologic Disorders Therapeutics Market Analysis
11.1 Africa Neurologic Disorders Therapeutics Consumption and Value Analysis
11.1.1 Africa Neurologic Disorders Therapeutics Market Under COVID-19
11.2 Africa Neurologic Disorders Therapeutics Consumption Volume by Types
11.3 Africa Neurologic Disorders Therapeutics Consumption Structure by Application
11.4 Africa Neurologic Disorders Therapeutics Consumption by Top Countries
11.4.1 Nigeria Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
11.4.2 South Africa Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
11.4.3 Egypt Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
11.4.4 Algeria Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
11.4.5 Morocco Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
Chapter 12 Oceania Neurologic Disorders Therapeutics Market Analysis
12.1 Oceania Neurologic Disorders Therapeutics Consumption and Value Analysis
12.2 Oceania Neurologic Disorders Therapeutics Consumption Volume by Types
12.3 Oceania Neurologic Disorders Therapeutics Consumption Structure by Application
12.4 Oceania Neurologic Disorders Therapeutics Consumption by Top Countries
12.4.1 Australia Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
12.4.2 New Zealand Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
Chapter 13 South America Neurologic Disorders Therapeutics Market Analysis
13.1 South America Neurologic Disorders Therapeutics Consumption and Value Analysis
13.1.1 South America Neurologic Disorders Therapeutics Market Under COVID-19
13.2 South America Neurologic Disorders Therapeutics Consumption Volume by Types
13.3 South America Neurologic Disorders Therapeutics Consumption Structure by Application
13.4 South America Neurologic Disorders Therapeutics Consumption Volume by Major Countries
13.4.1 Brazil Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
13.4.2 Argentina Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
13.4.3 Columbia Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
13.4.4 Chile Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
13.4.5 Venezuela Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
13.4.6 Peru Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
13.4.8 Ecuador Neurologic Disorders Therapeutics Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Neurologic Disorders Therapeutics Business
14.1 Biogen Inc.
14.1.1 Biogen Inc. Company Profile
14.1.2 Biogen Inc. Neurologic Disorders Therapeutics Product Specification
14.1.3 Biogen Inc. Neurologic Disorders Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.2 Novartis AG
14.2.1 Novartis AG Company Profile
14.2.2 Novartis AG Neurologic Disorders Therapeutics Product Specification
14.2.3 Novartis AG Neurologic Disorders Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.3 F. Hoffmann-La Roche Ltd.
14.3.1 F. Hoffmann-La Roche Ltd. Company Profile
14.3.2 F. Hoffmann-La Roche Ltd. Neurologic Disorders Therapeutics Product Specification
14.3.3 F. Hoffmann-La Roche Ltd. Neurologic Disorders Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.4 Johnson & Johnson Services Inc.
14.4.1 Johnson & Johnson Services Inc. Company Profile
14.4.2 Johnson & Johnson Services Inc. Neurologic Disorders Therapeutics Product Specification
14.4.3 Johnson & Johnson Services Inc. Neurologic Disorders Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.5 Pfizer Inc.
14.5.1 Pfizer Inc. Company Profile
14.5.2 Pfizer Inc. Neurologic Disorders Therapeutics Product Specification
14.5.3 Pfizer Inc. Neurologic Disorders Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
Chapter 15 Global Neurologic Disorders Therapeutics Market Forecast (2022-2027)
15.1 Global Neurologic Disorders Therapeutics Consumption Volume, Revenue and Price Forecast (2022-2027)
15.1.1 Global Neurologic Disorders Therapeutics Consumption Volume and Growth Rate Forecast (2022-2027)
15.1.2 Global Neurologic Disorders Therapeutics Value and Growth Rate Forecast (2022-2027)
15.2 Global Neurologic Disorders Therapeutics Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
15.2.1 Global Neurologic Disorders Therapeutics Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
15.2.2 Global Neurologic Disorders Therapeutics Value and Growth Rate Forecast by Regions (2022-2027)
15.2.3 North America Neurologic Disorders Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.4 East Asia Neurologic Disorders Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.5 Europe Neurologic Disorders Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.6 South Asia Neurologic Disorders Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.7 Southeast Asia Neurologic Disorders Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.8 Middle East Neurologic Disorders Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.9 Africa Neurologic Disorders Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.10 Oceania Neurologic Disorders Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.11 South America Neurologic Disorders Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.3 Global Neurologic Disorders Therapeutics Consumption Volume, Revenue and Price Forecast by Type (2022-2027)
15.3.1 Global Neurologic Disorders Therapeutics Consumption Forecast by Type (2022-2027)
15.3.2 Global Neurologic Disorders Therapeutics Revenue Forecast by Type (2022-2027)
15.3.3 Global Neurologic Disorders Therapeutics Price Forecast by Type (2022-2027)
15.4 Global Neurologic Disorders Therapeutics Consumption Volume Forecast by Application (2022-2027)
15.5 Neurologic Disorders Therapeutics Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
